Phase 3Update

BMN 401 (formerly INZ-701)

ENPP1 Deficiency

BMRNBiomarin Pharmaceutical Inc.

Expected catalystTBA

Catalyst overview

Event details

Drug or asset: BMN 401 (formerly INZ-701)
Development stage: Phase 3
Event type: Update
Indication: ENPP1 Deficiency

Research summary

What is being tracked?

This catalyst tracks a Phase 3 update for BMN 401 (formerly INZ-701) in ENPP1 Deficiency. The expected timing is based on the latest available company guidance and may change.

Development notes

10/27/25:- ENERGY 3 pivotal BMN 401 data in ENPP1 deficiency anticipated in H1 2026; potential launch 2027. 05/18/26:- ENERGY 3 Ph3 results: met PPi endpoint, missed RGI-C; next steps under review; meeting presentation planned.

Verification

Primary source

Confirm timing and program details against the company announcement or filing.

Open source